Skip to main content

The Hippo signaling pathway in leukemia: function, interaction, and carcinogenesis

Abstract

Cancer can be considered as a communication disease between and within cells; nevertheless, there is no effective therapy for the condition, and this disease is typically identified at its late stage. Chemotherapy, radiation, and molecular-targeted treatment are typically ineffective against cancer cells. A better grasp of the processes of carcinogenesis, aggressiveness, metastasis, treatment resistance, detection of the illness at an earlier stage, and obtaining a better therapeutic response will be made possible. Researchers have discovered that cancerous mutations mainly affect signaling pathways. The Hippo pathway, as one of the main signaling pathways of a cell, has a unique ability to cause cancer. In order to treat cancer, a complete understanding of the Hippo signaling system will be required. On the other hand, interaction with other pathways like Wnt, TGF-β, AMPK, Notch, JNK, mTOR, and Ras/MAP kinase pathways can contribute to carcinogenesis. Phosphorylation of oncogene YAP and TAZ could lead to leukemogenesis, which this process could be regulated via other signaling pathways. This review article aimed to shed light on how the Hippo pathway interacts with other cellular signaling networks and its functions in leukemia.

Introduction

Hematological malignancies include lymphoma, myeloma, myeloproliferative neoplasms, myelodysplastic syndromes, and leukemia with several subtypes [1]. Leukemia is divided into lymphocytic and myeloid, which these two mentioned groups include acute and chronic groups. In total, leukemia is a clonal disorder that results from genetic and epigenetic changes in a hematopoietic stem or progenitor cells that disrupt main processes such as self-renewal, proliferation, and differentiation [2, 3]. Leukemic stem cells have several critical signaling pathways regulating stem or progenitor cell proliferation, hematopoiesis, self-renewal, tissue repair, and apoptosis [4, 5]. Cell numbers are based on signaling pathways that communicate extracellular and intracellular stimuli to gene transcription. For example, constitutive and cytokine-mediated activation of the PI3K/Akt/mTOR signaling pathway is a common hallmark in patients with acute myeloid leukemia (AML), and regulation of this system is a feasible therapeutic option in the treatment of AML [4, 6].

A new signaling pathway, Hippo, has played a crucial role in maintaining organ size by regulating cell proliferation and death in the last decade [7]. Due to the severe overgrowth phenotype, Drosophila mosaic genetic screens first found many mutations in the Hippo signaling pathway [8]. Because of its remarkable effectiveness in controlling organ size, as well as its apparent significance to tissue regeneration and cancer, the Hippo signaling pathway immediately has drawn widespread interest [9]. Mammalian sterile 20-like 1/2 (MST1/2, also known STK4/3), Salvador (SAV1), Large tumor suppressor homolog 1/2 (LATS1/2), MOB kinase activator 1A/B (MOB1a/b), and Yes-associated protein (YAP)/Transcriptional co-activator with PDZ binding motif (TAZ, also known WWTR1) are the mammalian orthologs of Hpo, Sav, Wts, Mats, and Yki, respectively [10].

Furthermore, a mutation in the genes encoding Hippo signaling proteins can cause significant organ shape or growth parameters [11, 12]. For example, renal cell carcinoma [13], pancreatic cancer [14], breast cancer [15], cholangiocarcinoma [16], medulloblastoma [17], and hepatocellular cell carcinoma (HCC) [18] have all been found to have an abnormal expression of YAP [19,20,21]. After analyzing 177 pairs of HCC, standard samples with comprehensive clinical data were matched; it was revealed HCC patients with YAP have an independent prognostic marker for overall survival and disease-free survival [22].

There is insufficient evidence to identify the tissue specificity and frequency of pathway components and YAP mutations in human leukemias [23]. Several hematological malignancies have been linked to abnormal expression or genetic deficiencies in the Hippo signaling pathway, including acute leukemia and lymphoproliferative neoplasms [24, 25]. For example, in a study by Chen et al. they measured the effects of YAP knockdown on HL-60 cells. Their study found that inhibition of YAP inhibits proliferation and induces apoptosis in the cell line [25]. YAP was also overexpressed in CML cells in Li et al.'s study and inhibiting this protein reduced CML cell growth, triggered apoptosis, and lowered the expression of YAP target genes c-Myc and survivin. As a result, YAP could play a key role in CML cell proliferation and leukemogenesis. The genetic or pharmacological suppression of YAP offers a potential CML therapeutic option [26].

The standard of care for leukemia depends on many factors chosen based on age and overall health, the type of leukemia, and the stage of the disease [27]. Common treatments used to fight leukemia include chemotherapy, targeted therapy, radiation therapy, bone marrow transplant, immunotherapy, and engineering immune cells. Despite advances and extensions in existing treatments, leukemia is associated with low survival rates and poor prognosis in some cases [28]. Some patients resist the usual treatments, and some relapse after remission induction [29]. Therefore, a search in this signaling pathway is needed to find a new treatment strategy. In this study, we intend to address the Hippo signaling pathway, its interaction with other pathways, and its importance in different types of leukemia; perhaps by providing important and effective proteins, this signaling pathway provides a novel treatment strategy for leukemia.

Normal function of Hippo signaling pathway

The human Hippo pathway is based on a kinase signaling cascade including MST1 and MST2, as well as LATS1/2, SAV1 and MOB1, are two types of serine/threonine kinases [30]. When the Hippo pathway is inactive, unphosphorylated YAP/TAZ enters the nucleus and interacts with TEA DNA-binding proteins (TEAD1-4), then target genes regulated by this complex [31, 32] (Fig. 1). It is also proteolytically degraded when the Hippo pathway is activated [30, 33]. The Hippo pathway is dysregulated in cancer, enabling hyperproliferation, cellular invasion, metastasis, and chemoresistance [7, 34] (Fig. 1).

Fig. 1
figure 1

The core of the Hippo pathway. Multiple upstream signals regulate phosphorylation when the Hippo signaling pathway is activated, and MST1/2 kinases and SAV1 form a complex to phosphorylate and activate LATS1/2. YAP/TAZ proteins, two important downstream effectors of the Hippo pathway, are phosphorylated by LATS1/2 kinases. Phosphorylation of YAP/TAZ triggers the recruitment of 14-3-3 proteins, which promote cytoplasmic retention or proteolytic destruction. YAP/TAZ is not phosphorylated, localizes to the nucleus, forms a complex with transcription factor TEADs, and controls genes needed for endothelial cell proliferation, migration, and survival when the Hippo signaling pathway is turned off. LATS1/2 large tumor suppressor kinase; MST1/2 mammalian ste20-like kinase; SAV1 scaffold protein salvador; TAZ transcriptional co-activator with PDZ-binding motif; TEAD TEA domain family member; YAP Yes-associated protein

Prognostic value of YAP in cancer

The level of YAP1 protein is elevated a variety of cancers, including colorectal cancer (CRC), gastric cancer, esophageal squamous cell cancer (ESCC), human hepatocellular carcinoma (HCC), osteosarcoma [35,36,37,38]. The Hippo pathway can be promoted by YAP1 influence across multiple signaling pathways. Many studies have recently examined how tumorigenesis, tumor growth,, epithelial to mesenchymal transition (EMT), resistance to apoptosis and cancer prognosis are all affected by YAP1 [39]. YAP1 facilitates the growth of tumor cells and can lead to a poor prognosis in many cancers. Additionally, YAP1, a tumor suppressor, has been identified as an apoptotic factor induced by DNA damage in collaboration with p73 and promyelocytic leukemia [40, 41]. In CRC, YAP expression was associated to TNM stage, and expression level of cyclin D1; Wang et al. found that YAP expression was also linked to a short overall survival (OS) [42].

Qu et al. reported that downregulating YAP inhibited cell migration and invasion, and YAP expression level could be a new marker for predicting the prognosis of patients with ESCC [36]. According to Xia et al. high levels of YAP expression were positively correlated with TEAD4 gene expression in ovarian cancer patients [43]. As Barry et al. reported, complete loss of YAP was associated with poorer patient survival and high-grade, stage IV disease than YAP-positive groups. Furthermore, they found that YAP could act independently to restrict Wnt signaling [44]. A meta-analysis assessed the relationship between YAP1 expression and overall survival (OS) in 20 studies that was conducted on 2067 patients. As a result of this study, it is statistically significant that positive YAP1 expression can negatively impact OS and disease-free survival (DFS) in patients with cancer. It’s also been claimed that YAP1 could behave as a tumor suppressor gene in some cancers, which would be a poor prognostic factor [45].

The effect of Hippo signaling pathway in carcinogenesis

A wide range of upstream stimuli such as extracellular ligands, organ size, mechanotransduction, environmental stress, energy stress, and cell–cell contact controls YAP/TAZ activation in cancer cells [46]. The activation of YAP/TAZ via the dysregulation of the Hippo pathway is responsible for tumor development and confers cancer stem cell characteristics such as anoikis resistance, epithelial-to-mesenchymal transition, drug resistance, energy stress, and metastasis [47] (Fig. 2).

Fig. 2
figure 2

The Hippo pathway is dysregulated in cancer, enabling hyperproliferation, cellular invasion, metastasis, and chemoresistance. In these mechanisms, other signaling pathways affect the Hippo pathway that might lead to an increase or decrease YAP/TAZ complex level in the cytoplasm. EMT epithelial-mesenchymal transition; Yap Yes-associated protein

Hippo signaling pathway and interaction with other signaling pathways

Increased tissue development has been connected to YAP protein activation, as well as direct target genes like Myc, cell cycle regulators like CycE and E2F1, and apoptosis inhibitors like Diap1 and BIRC3, which have all been identified as contributory factors [48]. Other signaling pathways that may play a role in tissue growth control, including as the Wnt, Notch, EGFR, TGF, and Jak-STAT pathways, have also been identified as YAP protein targets [49] (Fig. 3). Upstream components of the Hippo pathway that adversely inhibit YAP activity, such as Merlin, Expanded, Kibra, AMOTL2, and LATS kinases, are another family of transcriptional targets [50]. Thousands of new potential targets have been discovered according to genome-wide expression profiling and chromatin binding. However, there are significant discrepancies between the lists of targets discovered in research involving various cell types, implying that much of the YAP response is tissue or cell-type specific [50, 51]. The transcription of several genes involved in cell proliferation, differentiation, and growth could be affected by these relationships. In this part, we looked at how Hippo signaling interacts with other important pathways in leukemia.

Fig. 3
figure 3

The Hippo pathway interacts with other signaling pathways. Akt protein kinase B; AMPK AMP-activated protein kinase; GPCR G protein-coupled receptor; JAK-STAT janus kinase and signal transducer and activator of transcription; MAPK mitogen-activated protein kinase; PI3K phosphatidylinositol-3-kinase; RAS rat sarcoma; SMAD mothers against decapentaplegic homolog; TGF transforming growth factor

Hippo and Wnt signaling pathways

In HSCs, Wnt signaling is critical for maintaining homeostasis [52, 53]. Low levels of Wnt activation promote hematopoietic stem cell (HSC) function, whereas high Wnt doses reduce hematopoiesis, demonstrating that canonical Wnt signaling regulates hematopoiesis in a dose-dependent manner [54]. As a result, the HSC requires a precisely controlled quantity of Wnt signaling pathway activity for self-renewal, survival, growth, and proliferation [55]. The stimulation of Wnt signaling is a frequent, varied feature of all leukemia types. For example, individuals with FLT3-mutated AML have high amounts of β-catenin, promoting in vivo leukemia growth in xenograft mice reconstituted AML cell lines with del(5q) [56]. Furthermore, abnormal expression of Wnt pathway components such as WNT1, WNT2b, and LEF-1 is found in many AML cases, so Wnt signaling has a predictive value in AML [57].

The canonical Wnt pathway is CML’s most seriously impacted Wnt system [58]. Because the fusion protein BCR-ABL may actively adjust β-catenin levels in cells. In CML progenitors, nuclear β-catenin increased resistance to intrinsic tyrosine kinase inhibitor (TKI) [59]. In CML, FoxM1/ β-catenin interaction is essential for controlling canonical Wnt signaling and cancer stem cell self-renewal, proliferation, and tumorigenesis [60].

According to accumulating evidence, YAP/TAZ, the key effectors in the Hippo signaling cascade, regulate β-catenin levels and activity by physically interacting with β-catenin or Dvl. The first clear evidence that YAP/TAZ inhibited the Wnt/β-catenin pathway came from a study identifying TAZ’s direct interaction with Dvl in the cytoplasm. After Wnt3a stimulation, TAZ knockdown increased Dvl phosphorylation, consequently increasing the nuclear accumulation of β-catenin. Suppressing an upstream kinase in the Hippo pathway improved the connection between TAZ and Dvl, resulting in Wnt/β-catenin pathway downregulation [61]. TAZ’s role as a modulator of Wnt/β-catenin signaling is an interesting hypothesis. The β-catenin destruction complex, which is made up of APC, Axin, and GSK3, has been demonstrated to modulate TAZ levels. β-catenin phosphorylated by GSK3 functions as a scaffold for the interaction of TAZ with the TrCP E3 ligase complex in the absence of Wnt signaling [62]. Wnt3a was also discovered to cause TAZ dephosphorylation and stabilization, allowing TAZ to be more easily localized in the nucleus.

Because Wnt signaling is essential in leukemia stem cells and the microenvironment, targeting Wnt signaling pathways could help treat leukemia [63]. Wnt and Hippo signaling pathways control similar biological processes; therefore, they could regulate each other’s activity for precise systems biology rather than function [64]. Furthermore, YAP can be developed as a novel treatment target based on the two pathways by the intersection of these two signaling pathways (Fig. 3).

Hippo pathway and mTOR interconnection

The cellular energy levels, amino acids, and other nutrients affect the rapamycin (mTOR) pathway [65]. Also, it is a master regulator of cell growth and metabolism and is an essential downstream effector of PI3K/AKT [66]. In recent trials, rapamycin and its analogs have shown significant anti-cancer activity in hematologic malignancies.

Given the importance of Hippo and mTOR signaling in growth control, it is not unexpected that links between them have been discovered. Mutation of the tuberous sclerosis complex (TSC), a critical negative regulator of mTORC1, resulted in an mTOR and autophagy-dependent overexpression of YAP proteins in a mouse cancer model [67]. mTORC2 phosphorylation reduces AMOT-YAP interaction, resulting in increased expression of YAP target genes [68]. In Drosophila, TOR suppression caused by genetic or dietary deficiency decreased Yki’s ability to access its target genes in the nucleus via an unknown mechanism [69]. Various signals can modulate the Hippo signaling in cancer stem cells, which are crucial in tumorigenesis.

The Ras/MAPK and Hippo signaling pathways

This signaling pathway is critical for transmitting proliferative signals from receptors on membrane-bound [70]. In human cancers, RAS-MAPK pathway genes with canonical strong activating somatic mutations are observed in AMLs [71]. They could influence pathway components and upstream activators such as NRAS, KRAS, BRAF, PTPN11, and FMS-related tyrosine kinase 3 (FLT3), as well as chromosomal translocations in leukemia (for example, BCR-ABL and TEL-PDGFR) [72]. CRAF (RAF-1), BRAF, and ARAF are the three members of the RAF family of serine/threonine kinases [73], and RAF-1 has also been discovered to function in MAPK pathway activation and STK3, also known as MST-2, is a serine/threonine kinase that regulates apoptosis [73]. MST-2 is one of the most important components of the Hippo pathway in mammals [74]; besides, MST-2 and YAP/TAZ are essential Hippo pathway effectors that have been linked to melanoma cell metastatic and invasive abilities [73].

YAP has also been shown to affect how cancer cells respond to inhibitors of the MAPK pathway [75, 76]. Tumorigenesis is the result of a complex interaction between a number of variables and pathways [77] (Fig. 3). The RAF-1/MST-2 connection, according to studies, could be a novel link between the MAPK and Hippo pathways. Ras (or Ras-related molecules), Raf, MEK, and ERK inhibition may be useful in the treatment of leukemia [78]. Many inhibitors have been applied for clinical trials or are under consideration by the pharmaceutical industry to target essential components of this system [79] (Fig. 3).

Hippo signaling pathway in leukemia

Deregulation of the Hippo signaling pathway is related to various solid tumors, including lung, breast, liver, and ovary [80]. Signaling pathways alteration can cause Leukemia, and among them, the Hippo pathway possesses significant effects on leukemia tumorigenesis [81]. The Hippo signaling pathway is an essential conservative pathway that helps regulate cell proliferation and apoptosis. Aberrant expression and mutation of core components in the Hippo signaling pathway such as MST1/2, LATS1/2, YAP, and TAZ easily promote cancer cell migration, invasion, and malignancy [82].

Many of the Hippo signaling pathway’s genes have been identified as tumor suppressors, such as MST1/2, SAV1, MOB1a/b, and LATS1/2, whereas others, such as YAP/TAZ, are oncogenes that stimulate malignant cells and allow them to proliferate uncontrollably [83]. Several studies have indicated that the activation of this pathway can be seen in many leukemia patients [84] (Table 1).

Table 1 Expression level of Hippo signaling pathway components in studies of leukemia

YAP and TAZ are functional effectors that regulate gene expression by co-activating various transcription factors involved in leukemogenesis, such as RUNX, TEADS, and SMADS [81, 85]. In Gholami et al. the expression analysis of LATS2 as a tumor suppresser gene in de novo AML subjects has revealed that LATS2 may be correlated with leukemogenesis. LATS2 gene was significantly overexpressed in patients who suffered AML compared to normal subjects [86] (Table 1). Another study revealed the MST2-ETV6 fusion gene as a core component of the Hippo signaling system, a possible oncogene, in AML patients with t (8;12) translocation [81].

In line with AML, Acute lymphocytic leukemia (ALL) low expression of the LATS2 gene was associated with ALL patients. Jimenez-Velasco et al. in their research, showed that low expression of the LATS2 gene is linked to promoter region methylation in leukemia cells [87] (Table 1). MST1 deficiency has also been shown to enhance T-cell ALL in the presence of mutagenic stimulation in other studies. MST1 deletion mice also develop lymphomas faster, and lymphocytes have been found to have chromosomal instability. KIBBRA, a critical upstream component in the Hippo signaling pathway, is heavily methylated, and this is the crucial underlying leukemogenesis event in this subtype of leukemia [21].

Also, chronic lymphocytic Leukemia (CLL) studies demonstrated that YAP mRNA expression was more significant than healthy controls. In CLL, characterized as lymphoma with B cell accumulation in the blood, bone marrow, and lymph nodes, epigenetic modulation of WWC1 expression was also observed. The WWC1 gene was methylated in around one-third of CLL patients' samples, resulting in lower WWC1 expression [84]. YAP is overexpressed in patients' chronic myelogenous leukemia (CML) cells. Hui li et al. found that the expression level of YAP is significantly higher in CML patients’ bone marrow mononuclear cells, indicating that YAP plays a critical role in CML leukemogenesis. The result of another survey has revealed that LATS2 and AURKA, as well as TAZ and AURKB at advanced phases, are overexpressed compared to healthy control groups, which powerfully demonstrate the role of this signaling pathway deregulation in the pathogenesis of CML patients [26] (Table 1).

Crosstalk between the Hippo pathway and miRNAs

MicroRNAs are highly involved in the Hippo pathway regulation. Several studies have shed light on the role of the Hippo pathway in tumorigenesis in various types of cancer such as breast, liver, gastric, glioblastoma cancers [88]. Importantly, miRNAs have been revealed to directly target and regulate the core components of the Hippo pathway. For example, miR-874-3p is significantly downregulated in colorectal cancer (CRC) tissue compared to normal tissues. MiR-874-3p by inhibition the YAP expression in the Hippo pathway resulting in the inactivation of the TEAD transcription [89]. Another research has revealed that miR-665 could promote proliferation and metastasis in hepatocellular carcinoma by inhibiting Hippo pathway activity [90]. In leukemia patients, which is the main topic of our article, several studies have been conducted to address the pivotal role of different microRNAs on the regulation of Hippo pathway components [91]. miR-550-1 acts as a tumor suppressor through the Hippo signaling pathway in AML. In a survey, microarray analysis revealed that miR-550-1 was significantly downregulated in the AML sample from the human patients, probably due to hypermethylation of the associated CpG islands. WWTR1 gene is considered a downstream target of miR-550-1, reducing the WWTR1 stability [92]. The information of the other microRNAs that contributed to the Hippo pathway in leukemia is described in Table 2.

Table 2 The contribution of microRNAs demonstrated to be involved in the Hippo pathway in leukemia

New pharmacological inhibitor targeting YAP

Despite advances in cancer treatment in recent decades, most patients respond poorly after a certain number of treatment cycles, and researchers also face significant challenges in treating cancer [93]. We summarize the pharmacological agents targeting the Hippo pathway to eliminate cancer cells. Dasatinib and statins represent compounds that inhibit YAP/TAZ activity via activating LATS [94]. Verteporfin represents compounds that inhibit the interaction between YAP/TAZ and TEAD [95]. Blebbistatin, Botulinum toxin C3 and LY294002PDK1 inhibitor II inhibit YAP/TAZ nuclear localization and transcriptional activity [96, 97]. Discoveries imply the suppression of YAP/TAZ-driven transcription via CDK9 inhibitors [98].

Simvastatin also has a potent YAP/TAZ inhibiting action. Ibudilast (a PDE4 selective inhibitor) and Forskolin can promote YAP phosphorylation by preventing cAMP breakdown, implying that PDE inhibitors may be useful in the treatment of cancers with YAP oncogenic activity [99, 100]. Dobutamine’s possible anti-cancer activity was recently investigated in a variety of cancer types. Dobutamine causes phosphorylation of YAP-Ser127, which causes YAP-dependent gene transcription to be suppressed [101]. Latrunculin B and cytochalasin D, which disrupt the actin cytoskeleton, limit YAP activation in response to cell attachment to the ECM-Inhibition of nuclear YAP localization via increased LATS activity [102]. Dihydrexidine increases YAP phosphorylation and inhibits Hippo signaling pathway [103] (Fig. 4).

Fig. 4
figure 4

New druggable agent effective in targeting YAP. The figure shows the drug agents that can be effective in the Hippo signaling pathway. Some of these drugs inhibit YAP/TAZ nuclear localization or block the transcription of target genes. Some others lead to the degradation of these proteins by increasing LATS activity and phosphorylation of the YAP/TAZ complex. LATS large tumor suppressor kinase; Yap Yes-associated protein

Conclusion and future perspective

Hippo signaling plays an important role in tumor initiation, invasion, drug resistance, metastatic potential, and self-renewal of cancer stem cells, as well as developmental control. According to studies on this signaling pathway, YAP as a tumor suppressor gene can be involved in many types of cancer. In leukemias, although not much information is available, the increased expression of this protein shows a significant relationship with the poor prognosis of patients. Therefore, the study of the mechanism of action YAP and the factors affecting its inhibition in cancer can be proposed as new pharmacological agents in leukemia treatment.

Availability of data and materials

The primary data for this study is available from the authors on direct request.

Abbreviations

Akt:

Protein kinase B

ALL:

Acute lymphocytic leukemia

AML:

Acute myeloid leukemia

AMPK:

AMP-activated protein kinase

APC:

Adenomatous polyposis coli

APL:

Acute promyelocytic leukemia

AURKA/B:

Aurora kinase A/B

CRC:

Colorectal cancer

CLL:

Chronic lymphocytic leukemia

CML:

Chronic myelogenous leukemia

DVL:

Dishevelled

ERK:

Extracellular signal-regulated kinase

FOXH1:

Forkhead box H1

GLUT3:

Glucose transporter 3

GSK3B:

Glycogen synthase kinase 3 beta

HCC:

Hepatocellular carcinoma

HSC:

Hematopoietic stem cell

JNK:

Jun N-terminal kinase

LATS2:

Large tumor suppressor kinase 2

LEF1:

Lymphoid enhancer binding factor 1

LKB1:

Liver kinase B1

MAP:

Mitogen-activated protein

Mats:

Mob as tumor suppressor

MEK:

MAPK/ERK kinase

MOB1a/b:

MOB kinase activator 1A/B

MOBKL2A:

Mps one binder kinase activator-Like 2A

MST1/2:

Macrophage stimulating 1/2

mTOR:

Mammalian target of rapamycin

KIBRA:

Kidney and brain protein

PI3K:

Phosphatidylinositol-3-kinase

PTEN:

Phosphatase and tensin homolog

Sav:

Scaffold protein salvador

SMAD:

Mothers against decapentaplegic homolog

STK4/3:

Serine/threonine kinase 3/4

TAZ:

Tafazzin

TAZ:

Transcriptional co-activator with PDZ binding motif

TCF:

T-cell factor

TEAD1-4:

TEA DNA-binding proteins

TGF:

Transforming growth factor

Wts:

Protein kinase warts

WWTR1:

WW domain-containing transcription regulator protein 1

YAP:

Yes-associated Protein

Yki:

Yorkie

References

  1. Jian J, Qiao Y, Li Y, Guo Y, Ma H, Liu B. Mutations in chronic myelomonocytic leukemia and their prognostic relevance. Clin Transl Oncol. 2021;23(9):1731-1742. https://doi.org/10.1007/s12094-021-02585-x.

    Article  PubMed  Google Scholar 

  2. Pang WW, Schrier SL, Weissman IL. Age-associated changes in human hematopoietic stem cells. Semin Hematol. 2017;54(1):39-42. https://doi.org/10.1053/j.seminhematol.2016.10.004

    Google Scholar 

  3. Kahn JM, Keegan TH, Tao L, Abrahão R, Bleyer A, Viny AD. Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma. Cancer. 2016;122(17):2723–30. https://doi.org/10.1002/cncr.30089.

    Article  PubMed  Google Scholar 

  4. Siveen KS, Uddin S, Mohammad RM. Targeting acute myeloid leukemia stem cell signaling by natural products. Mol Cancer. 2017;16(1):13. https://doi.org/10.1186/s12943-016-0571-x.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Riether C, Schürch CM, Ochsenbein AF. Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ. 2015;22(2):187–98. https://doi.org/10.1038/cdd.2014.89.

    Article  PubMed  CAS  Google Scholar 

  6. Nepstad I, Hatfield KJ, Aasebø E, Hernandez-Valladares M, Brenner AK, Bartaula-Brevik S, Berven F, Selheim F, Skavland J, Gjertsen BT, Reikvam H, Bruserud Ø. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison. Expert Opin Ther Targets. 2018;22(7):639–53. https://doi.org/10.1080/14728222.2018.1487401.

    Article  PubMed  CAS  Google Scholar 

  7. Cho YS, Li S, Wang X, Zhu J, Zhuo S, Han Y, Yue T, Yang Y, Jiang J. CDK7 regulates organ size and tumor growth by safeguarding the Hippo pathway effector Yki/Yap/Taz in the nucleus. Genes Dev. 2020;34(1–2):53–71. https://doi.org/10.1101/gad.333146.119.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Ehmer U, Sage J. Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway. Mol Cancer Res. 2016;14(2):127–40. https://doi.org/10.1158/1541-7786.

    Article  PubMed  CAS  Google Scholar 

  9. Kodaka M, Hata Y. The mammalian Hippo pathway: regulation and function of YAP1 and TAZ. Cell Mol Life Sci. 2015;72(2):285–306. https://doi.org/10.1007/s00018-014-1742-9.

    Article  PubMed  CAS  Google Scholar 

  10. Sebio A, Lenz HJ. Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor. Clin Cancer Res. 2015;21(22):5002–7. https://doi.org/10.1158/1078-0432.CCR-15-0411.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Irvine KD, Harvey KF. Control of organ growth by patterning and hippo signaling in Drosophila. Cold Spring Harb Perspect Biol. 2015;7(6):a019224. https://doi.org/10.1101/cshperspect.a019224

    Article  Google Scholar 

  12. Mach J, Atkins M, Gajewski KM, Mottier-Pavie V, Sansores-Garcia L, Xie J, Mills RA, Kowalczyk W, Van Huffel L, Mills GB, Halder G. Modulation of the Hippo pathway and organ growth by RNA processing proteins. Proc Natl Acad Sci U S A. 2018;115(42):10684–9. https://doi.org/10.1073/pnas.1807325115.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Yin L, Li W, Xu A, Shi H, Wang K, Yang H, Wang R, Peng B. SH3BGRL2 inhibits growth and metastasis in clear cell renal cell carcinoma via activating hippo/TEAD1-Twist1 pathway. EBioMedicine. 2020;51:102596. https://doi.org/10.1016/j.ebiom.2019.12.005.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ren D, Sun Y, Zhang D, Li D, Liu Z, Jin X, Wu H. SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis. Cancer Lett. 2021;28(519):277–88. https://doi.org/10.1016/j.canlet.2021.07.035.

    Article  CAS  Google Scholar 

  15. Kim J, Jang G, Sim SH, Park IH, Kim K, Park C. SMARCA4 depletion induces cisplatin resistance by activating YAP1-Mediated epithelial-to-mesenchymal transition in triple-negative breast cancer. Cancers (Basel). 2021;13(21):5474. https://doi.org/10.3390/cancers13215474.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Xu KD, Miao Y, Li P, Li PP, Liu J, Li J, Cao F. Licochalcone A inhibits cell growth through the downregulation of the Hippo pathway via PES1 in cholangiocarcinoma cells. Environ Toxicol. 2021. https://doi.org/10.1002/tox.23422.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Orr BA, Bai H, Odia Y, Jain D, Anders RA, Eberhart CG. Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth. J Neuropathol Exp Neurol. 2011;70(7):568–77. https://doi.org/10.1097/NEN.0b013e31821ff8d8.

    Article  PubMed  CAS  Google Scholar 

  18. Sohn BH, Shim JJ, Kim SB, Jang KY, Kim SM, Kim JH, Hwang JE, Jang HJ, Lee HS, Kim SC, Jeong W, Kim SS, Park ES, Heo J, Kim YJ, Kim DG, Leem SH, Kaseb A, Hassan MM, Cha M, Chu IS, Johnson RL, Park YY, Lee JS. Inactivation of Hippo pathway is significantly associated with poor prognosis in hepatocellular carcinoma. Clin Cancer Res. 2016;22(5):1256–64. https://doi.org/10.1158/1078-0432.CCR-15-1447.

    Article  PubMed  CAS  Google Scholar 

  19. Cao JJ, Zhao XM, Wang DL, Chen KH, Sheng X, Li WB, Li MC, Liu WJ, He J. YAP is overexpressed in clear cell renal cell carcinoma and its knockdown reduces cell proliferation and induces cell cycle arrest and apoptosis. Oncol Rep. 2014;32(4):1594–600. https://doi.org/10.3892/or.2014.3349.

    Article  PubMed  CAS  Google Scholar 

  20. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT, Luk JM. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009;115(19):4576–85. https://doi.org/10.1002/cncr.24495.

    Article  PubMed  CAS  Google Scholar 

  21. Wu R, Yang H, Wan J, Deng X, Chen L, Hao S, Ma L. Knockdown of the Hippo transducer YAP reduces proliferation and promotes apoptosis in the Jurkat leukemia cell. Mol Med Rep. 2018;18(6):5379–88. https://doi.org/10.3892/mmr.2018.9556.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Philippe C, Pinson B, Dompierre J, Pantesco V, Viollet B, Daignan-Fornier B, Moenner M. AICAR Antiproliferative Properties Involve the AMPK-Independent Activation of the Tumor Suppressors LATS 1 and 2. Neoplasia. 2018;20(6):555–62. https://doi.org/10.1016/j.neo.2018.03.006.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Li FL, Guan KL. The two sides of Hippo pathway in cancer. Semin Cancer Biol. 2021. https://doi.org/10.1016/j.semcancer.2021.07.006.

    Article  PubMed  Google Scholar 

  24. Oceandy D, Amanda B, Ashari FY, Faizah Z, Azis MA, Stafford N. The Cross-Talk Between the TNF-α and RASSF-Hippo Signalling Pathways. Int J Mol Sci. 2019;20(9):2346. https://doi.org/10.3390/ijms20092346.

    Article  PubMed Central  CAS  Google Scholar 

  25. Chen M, Wang J, Yao SF, Zhao Y, Liu L, Li LW, Xu T, Gan LG, Xiao CL, Shan ZL, Zhong L, Liu BZ. Effect of YAP Inhibition on Human Leukemia HL-60 Cells. Int J Med Sci. 2017;14(9):902–10. https://doi.org/10.7150/ijms.19965.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Li H, Huang Z, Gao M, Huang N, Luo Z, Shen H, Wang X, Wang T, Hu J, Feng W. Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo. J Exp Clin Cancer Res. 2016;35(1):134. https://doi.org/10.1186/s13046-016-0414-z.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Kumar CC. Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer. 2011;2(2):95–107. https://doi.org/10.1177/1947601911408076.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. Cell Res. 2017;27(1):38–58. https://doi.org/10.1038/cr.2016.154.

    Article  PubMed  CAS  Google Scholar 

  29. Wayne AS, Giralt S, Kröger N, Bishop MR. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction. Biol Blood Marrow Transplant. 2013;19(11):1534–6. https://doi.org/10.1016/j.bbmt.2013.08.016.

    Article  PubMed  Google Scholar 

  30. Boopathy GTK, Hong W. Role of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis. Front Cell Dev Biol. 2019;7:49. https://doi.org/10.3389/fcell.2019.00049.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Heng BC, Zhang X, Aubel D, Bai Y, Li X, Wei Y, Fussenegger M, Deng X. An overview of signaling pathways regulating YAP/TAZ activity. Cell Mol Life Sci. 2021;78(2):497–512. https://doi.org/10.1007/s00018-020-03579-8.

    Article  PubMed  CAS  Google Scholar 

  32. Callus BA, Finch-Edmondson ML, Fletcher S, Wilton SD. YAPping about and not forgetting TAZ. FEBS Lett. 2019;593(3):253–76. https://doi.org/10.1002/1873-3468.13318.

    Article  PubMed  CAS  Google Scholar 

  33. Park JH, Shin JE, Park HW. The Role of Hippo Pathway in Cancer Stem Cell Biology. Mol Cells. 2018;41(2):83–92. https://doi.org/10.14348/molcells.2018.2242.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Karvonen H, Barker H, Kaleva L, Niininen W, Ungureanu D. Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and BMI-1 Pathways. Cells. 2019;8(8):812. https://doi.org/10.3390/cells8080812.

    Article  PubMed Central  CAS  Google Scholar 

  35. Xu Z, Wang H, Gao L, Zhang H, Wang X. YAP Levels Combined with Plasma CEA Levels Are Prognostic Biomarkers for Early-Clinical-Stage Patients of Colorectal Cancer. Biomed Res Int. 2019;2019:2170830. https://doi.org/10.1155/2019/2170830

    Article  PubMed  PubMed Central  Google Scholar 

  36. Qu Y, Zhang L, Wang J, Chen P, Jia Y, Wang C, Yang W, Wen Z, Song Q, Tan B, Cheng Y. Yes-associated protein (YAP) predicts poor prognosis and regulates progression of esophageal squamous cell cancer through epithelial-mesenchymal transition. Exp Ther Med. 2019;18(4):2993–3001. https://doi.org/10.3892/etm.2019.7896.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Shu B, Zhai M, Miao X, He C, Deng C, Fang Y, Luo M, Liu L, Liu S. Serotonin and YAP/VGLL4 Balance Correlated with Progression and Poor Prognosis of Hepatocellular Carcinoma. Sci Rep. 2018;8(1):9739. https://doi.org/10.1038/s41598-018-28075-9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Bouvier C, Macagno N, Nguyen Q, Loundou A, Jiguet-Jiglaire C, Gentet JC, Jouve JL, Rochwerger A, Mattei JC, Bouvard D, Salas S. Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma. Oncotarget. 2016;7(40):64702–10. https://doi.org/10.18632/oncotarget.11876.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA. Expression of Yes-associated protein in common solid tumors. Hum Pathol. 2008;39(11):1582–9. https://doi.org/10.1016/j.humpath.2008.04.012.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Yu SJ, Hu JY, Kuang XY, Luo JM, Hou YF, Di GH, Wu J, Shen ZZ, Song HY, Shao ZM. MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clin Cancer Res. 2013;19(6):1389–99. https://doi.org/10.1158/1078-0432.CCR-12-1959.

    Article  PubMed  CAS  Google Scholar 

  41. Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G, Pandolfi PP, Givol D, Strano S, Lu X, Blandino G. PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell. 2008;32(6):803–14. https://doi.org/10.1016/j.molcel.2008.11.019.

    Article  PubMed  CAS  Google Scholar 

  42. Wang Y, Xie C, Li Q, Xu K, Wang E. Clinical and prognostic significance of Yes-associated protein in colorectal cancer. Tumour Biol. 2013;34(4):2169–74. https://doi.org/10.1007/s13277-013-0751-x.

    Article  PubMed  CAS  Google Scholar 

  43. Xia Y, Chang T, Wang Y, Liu Y, Li W, Li M, Fan HY. YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PLoS One. 2014;9(3):e91770 https://doi.org/10.1371/journal.pone.0091770 (Erratum. In: PLoS One. 2016;11(3):e0152712)

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, Fuchs CS, Magness ST, Smits R, Ogino S, Kuo CJ, Camargo FD. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature. 2013;493(7430):106–10. https://doi.org/10.1038/nature11693.

    Article  PubMed  CAS  Google Scholar 

  45. Sun Z, Xu R, Li X, Ren W, Ou C, Wang Q, Zhang H, Zhang X, Ma J, Wang H, Li G. Prognostic Value of Yes-Associated Protein 1 (YAP1) in Various Cancers: A Meta-Analysis. PLoS One. 2015;10(8):e0135119. https://doi.org/10.1371/journal.pone.0135119.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Totaro A, Panciera T, Piccolo S. YAP/TAZ upstream signals and downstream responses. Nat Cell Biol. 2018;20(8):888–99. https://doi.org/10.1038/s41556-018-0142-z.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Guo Y, Cui J, Ji Z, Cheng C, Zhang K, Zhang C, Chu M, Zhao Q, Yu Z, Zhang Y, Fang YX, Gao WQ, Zhu HH. miR-302/367/LATS2/YAP pathway is essential for prostate tumor-propagating cells and promotes the development of castration resistance. Oncogene. 2017;36(45):6336–47. https://doi.org/10.1038/onc.2017.240.

    Article  PubMed  CAS  Google Scholar 

  48. Varelas X. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development. 2014;141(8):1614–26. https://doi.org/10.1242/dev.102376.

    Article  PubMed  CAS  Google Scholar 

  49. Hansen CG, Moroishi T, Guan KL. YAP and TAZ: a nexus for Hippo signaling and beyond. Trends Cell Biol. 2015;25(9):499–513. https://doi.org/10.1016/j.tcb.2015.05.002.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Yu FX, Zhao B, Guan KL. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell. 2015;163(4):811–28. https://doi.org/10.1016/j.cell.2015.10.044.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Varelas X, Sakuma R, Samavarchi-Tehrani P, Peerani R, Rao BM, Dembowy J, Yaffe MB, Zandstra PW, Wrana JL. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol. 2008;10(7):837–48. https://doi.org/10.1038/ncb1748.

    Article  PubMed  CAS  Google Scholar 

  52. Chavali M, Klingener M, Kokkosis AG, Garkun Y, Felong S, Maffei A, Aguirre A. Non-canonical Wnt signaling regulates neural stem cell quiescence during homeostasis and after demyelination. Nat Commun. 2018;9(1):36. https://doi.org/10.1038/s41467-017-02440-0.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. Wang LT, Lin MH, Liu KY, Chiou SS, Wang SN, Chai CY, Tseng LW, Chiou HC, Wang HC, Yokoyama KK, Hsu SH, Huang SK. WLS/wntless is essential in controlling dendritic cell homeostasis via a WNT signaling-independent mechanism. Autophagy. 2021;14:1–16. https://doi.org/10.1080/15548627.2021.1907516.

    Article  CAS  Google Scholar 

  54. Hétu-Arbour R, Tlili M, Bandeira Ferreira FL, Abidin BM, Kwarteng EO, Heinonen KM. Cell-intrinsic Wnt4 promotes hematopoietic stem and progenitor cell self-renewal. Stem Cells. 2021;39(9):1207–20. https://doi.org/10.1002/stem.3385.

    Article  PubMed  CAS  Google Scholar 

  55. Krishnan M, Kumar S, Kangale LJ, Ghigo E, Abnave P. The act of controlling adult stem cell dynamics: Insights from animal models. Biomolecules. 2021;11(5):667. https://doi.org/10.3390/biom11050667.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Yao Y, Li F, Huang J, Jin J, Wang H. Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development. Exp Hematol Oncol. 2021;10(1):39. https://doi.org/10.1186/s40164-021-00233-2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Soares-Lima SC, Pombo-de-Oliveira MS, Carneiro FRG. The multiple ways Wnt signaling contributes to acute leukemia pathogenesis. J Leukoc Biol. 2020;108(4):1081–99. https://doi.org/10.1002/JLB.2MR0420-707R.

    Article  PubMed  CAS  Google Scholar 

  58. Liu Z, Wang P, Wold EA, Song Q, Zhao C, Wang C, Zhou J. Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer. J Med Chem. 2021;64(8):4257–88. https://doi.org/10.1021/acs.jmedchem.0c01799.

    Article  PubMed  CAS  Google Scholar 

  59. Eiring AM, Khorashad JS, Anderson DJ, Yu F, Redwine HM, Mason CC, Reynolds KR, Clair PM, Gantz KC, Zhang TY, Pomicter AD, Kraft IL, Bowler AD, Johnson K, Partlin MM, O'Hare T, Deininger MW. β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia. 2015;29(12):2328–37. https://doi.org/10.1038/leu.2015.196.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Jin B, Wang C, Li J, Du X, Ding K, Pan J. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clin Cancer Res. 2017;23(3):789–803. https://doi.org/10.1158/1078-0432.CCR-16-0226.

    Article  PubMed  CAS  Google Scholar 

  61. Varelas X, Miller BW, Sopko R, Song S, Gregorieff A, Fellouse FA, Sakuma R, Pawson T, Hunziker W, McNeill H, Wrana JL, Attisano L. The Hippo pathway regulates Wnt/beta-catenin signaling. Dev Cell. 2010;18(4):579–91. https://doi.org/10.1016/j.devcel.2010.03.007.

    Article  PubMed  CAS  Google Scholar 

  62. Azzolin L, Zanconato F, Bresolin S, Forcato M, Basso G, Bicciato S, Cordenonsi M, Piccolo S. Role of TAZ as mediator of Wnt signaling. Cell. 2012;151(7):1443–56. https://doi.org/10.1016/j.cell.2012.11.027.

    Article  PubMed  CAS  Google Scholar 

  63. Staal FJ, Famili F, Garcia Perez L, Pike-Overzet K. Aberrant wnt signaling in Leukemia. Cancers (Basel). 2016;8(9):78. https://doi.org/10.3390/cancers8090078.

    Article  CAS  Google Scholar 

  64. Takahashi T, Shiraishi A, Murata J. The Coordinated Activities of nAChR and Wnt Signaling Regulate Intestinal Stem Cell Function in Mice. Int J Mol Sci. 2018;19(3):738. https://doi.org/10.3390/ijms19030738.

    Article  PubMed Central  CAS  Google Scholar 

  65. Yang X, Yang C, Farberman A, Rideout TC, de Lange CF, France J, Fan MZ. The mammalian target of rapamycin-signaling pathway in regulating metabolism and growth. J Anim Sci. 2008;86(14 Suppl):E36–50. https://doi.org/10.2527/jas.2007-0567.

    Article  PubMed  CAS  Google Scholar 

  66. Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ. 2002;9(2):99–100. https://doi.org/10.1038/sj.cdd.4400978.

    Article  PubMed  CAS  Google Scholar 

  67. Liang K, Zhou G, Zhang Q, Li J, Zhang C. Expression of hippo pathway in colorectal cancer. Saudi J Gastroenterol. 2014;20(3):188–94. https://doi.org/10.4103/1319-3767.133025.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Artinian N, Cloninger C, Holmes B, Benavides-Serrato A, Bashir T, Gera J. Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness. J Biol Chem. 2015;290(32):19387–401. https://doi.org/10.1074/jbc.M115.656587.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. Parker J, Struhl G. Scaling the Drosophila Wing: TOR-Dependent Target Gene Access by the Hippo Pathway Transducer Yorkie. PLoS Biol. 2015;13(10):e1002274. https://doi.org/10.1371/journal.pbio.1002274.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  70. Degirmenci U, Wang M, Hu J. Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy. Cells. 2020;9(1):198. https://doi.org/10.3390/cells9010198.

    Article  PubMed Central  CAS  Google Scholar 

  71. Kishtagari A, Levine RL, Viny AD. Driver mutations in acute myeloid leukemia. Curr Opin Hematol. 2020;27(2):49–57. https://doi.org/10.1097/MOH.0000000000000567.

    Article  PubMed  Google Scholar 

  72. Rocca S, Carrà G, Poggio P, Morotti A, Brancaccio M. Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia. Mol Cancer. 2018;17(1):40. https://doi.org/10.1186/s12943-018-0774-4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. Feng R, Gong J, Wu L, Wang L, Zhang B, Liang G, Zheng H, Xiao H. MAPK and Hippo signaling pathways crosstalk via the RAF-1/MST-2 interaction in malignant melanoma. Oncol Rep. 2017;38(2):1199–205. https://doi.org/10.3892/or.2017.5774.

    Article  PubMed  CAS  Google Scholar 

  74. Ma S, Meng Z, Chen R, Guan KL. The Hippo Pathway: Biology and Pathophysiology. Annu Rev Biochem. 2019;88:577–604. https://doi.org/10.1146/annurev-biochem-013118-111829.

    Article  PubMed  CAS  Google Scholar 

  75. Hasegawa K, Fujii S, Matsumoto S, Tajiri Y, Kikuchi A, Kiyoshima T. YAP signaling induces PIEZO1 to promote oral squamous cell carcinoma cell proliferation. J Pathol. 2021;253(1):80–93. https://doi.org/10.1002/path.5553.

    Article  PubMed  CAS  Google Scholar 

  76. Yuan J, Dong X, Yap J, Hu J. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol. 2020;13(1):113. https://doi.org/10.1186/s13045-020-00949-4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Ferreira AR, Ramalho AC, Marques M, Ribeiro D. The Interplay between Antiviral Signalling and Carcinogenesis in Human Papillomavirus Infections. Cancers (Basel). 2020;12(3):646. https://doi.org/10.3390/cancers12030646.

    Article  PubMed Central  CAS  Google Scholar 

  78. Chen Z, Li S, Mo J, Hawley E, Wang Y, He Y, Brosseau JP, Shipman T, Clapp DW, Carroll TJ, Le LQ. Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling. JCI Insight. 2020;5(20): https://doi.org/10.1172/jci.insight.141514.

    Article  PubMed Central  Google Scholar 

  79. Duda P, Akula SM, Abrams SL, Steelman LS, Martelli AM, Cocco L, Ratti S, Candido S, Libra M, Montalto G, Cervello M, Gizak A, Rakus D, McCubrey JA. Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. Cells. 2020;9(5):1110. https://doi.org/10.3390/cells9051110.

    Article  PubMed Central  CAS  Google Scholar 

  80. Mohammadi S, Arefnezhad R, Danaii S, Yousefi M. New insights into the core Hippo signaling and biological macromolecules interactions in the biology of solid tumors. Biofactors. 2020;46(4):514–30. https://doi.org/10.1002/biof.1634.

    Article  PubMed  CAS  Google Scholar 

  81. Allegra A, Pioggia G, Innao V, Musolino C, Gangemi S. New Insights into YES-Associated Protein Signaling Pathways in Hematological Malignancies: Diagnostic and Therapeutic Challenges. Cancers (Basel). 2021;13(8):1981. https://doi.org/10.3390/cancers13081981.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Vigneau AL, Rico C, Boerboom D, Paquet M. Statins downregulate YAP and TAZ and exert anti-cancer effects in canine mammary tumor cells. Vet Comp Oncol. 2021;. https://doi.org/10.1111/vco.12789.

    Article  PubMed  Google Scholar 

  83. Masliantsev K, Karayan-Tapon L, Guichet PO. Hippo signaling pathway in gliomas. Cells. 2021;10(1):184. https://doi.org/10.3390/cells10010184.

    Article  PubMed  CAS  Google Scholar 

  84. Höffken V, Hermann A, Pavenstädt H, Kremerskothen J. WWC proteins: Important regulators of hippo signaling in cancer. Cancers (Basel). 2021;13(2):306. https://doi.org/10.3390/cancers13020306.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Kovar H, Bierbaumer L, Radic-Sarikas B. The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis. Cells. 2020;9(4):972. https://doi.org/10.3390/cells9040972.

    Article  PubMed Central  CAS  Google Scholar 

  86. Gholami M, Mirfakhraie R, Movafagh A, Jalaeekhoo H, Kalahroodi R, Zare-Abdollahi D, Zare-Karizi S. The expression analysis of LATS2 gene in de novo AML patients. Med Oncol. 2014;31(5):961. https://doi.org/10.1007/s12032-014-0961-0.

    Article  PubMed  CAS  Google Scholar 

  87. Jiménez-Velasco A, Román-Gómez J, Agirre X, Barrios M, Navarro G, Vázquez I, Prósper F, Torres A, Heiniger A. Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia. Leukemia. 2005;19(12):2347–50. https://doi.org/10.1038/sj.leu.2403974.

    Article  PubMed  CAS  Google Scholar 

  88. Han Y. Analysis of the role of the Hippo pathway in cancer. J Transl Med. 2019;17(1):116. https://doi.org/10.1186/s12967-019-1869-4.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Que K, Tong Y, Que G, Li L, Lin H, Huang S, Wang R, Tang L. Downregulation of miR-874-3p promotes chemotherapeutic resistance in colorectal cancer via inactivation of the Hippo signaling pathway. Oncol Rep. 2017;38(6):3376–86. https://doi.org/10.3892/or.2017.6041.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  90. Hu Y, Yang C, Yang S, Cheng F, Rao J, Wang X. miR-665 promotes hepatocellular carcinoma cell migration, invasion, and proliferation by decreasing Hippo signaling through targeting PTPRB. Cell Death Dis. 2018;9(10):954. https://doi.org/10.1038/s41419-018-0978-y.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  91. Zhu R, Zhao W, Fan F, Tang L, Liu J, Luo T, Deng J, Hu Y. A 3-miRNA signature predicts prognosis of pediatric and adolescent cytogenetically normal acute myeloid leukemia. Oncotarget. 2017;8(24):38902–13. https://doi.org/10.18632/oncotarget.17151.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Hu C, Yu M, Li C, Wang Y, Li X, Ulrich B, Su R, Dong L, Weng H, Huang H, Jiang X, Chen J, Jin J. miR-550-1 functions as a tumor suppressor in acute myeloid leukemia via the hippo signaling pathway. Int J Biol Sci. 2020;16(15):2853–67. https://doi.org/10.7150/ijbs.44365.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  93. Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T, Yang S. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6(1):201. https://doi.org/10.1038/s41392-021-00572-w.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Oku Y, Nishiya N, Shito T, Yamamoto R, Yamamoto Y, Oyama C, Uehara Y. Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers. FEBS Open Bio. 2015;5:542–9. https://doi.org/10.1016/j.fob.2015.06.007.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  95. Wang C, Zhu X, Feng W, Yu Y, Jeong K, Guo W, Lu Y, Mills GB. Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. Am J Cancer Res. 2015;6(1):27–37.

    PubMed  PubMed Central  CAS  Google Scholar 

  96. Das A, Fischer RS, Pan D, Waterman CM. YAP Nuclear Localization in the Absence of Cell-Cell Contact Is Mediated by a Filamentous Actin-dependent, Myosin II- and Phospho-YAP-independent Pathway during Extracellular Matrix Mechanosensing. J Biol Chem. 2016;291(12):6096–110. https://doi.org/10.1074/jbc.M115.708313.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  97. Mo JS, Yu FX, Gong R, Brown JH, Guan KL. Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). Genes Dev. 2012;26(19):2138–43. https://doi.org/10.1101/gad.197582.112.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  98. Galli GG, Carrara M, Yuan WC, Valdes-Quezada C, Gurung B, Pepe-Mooney B, Zhang T, Geeven G, Gray NS, de Laat W, Calogero RA, Camargo FD. YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers. Mol Cell. 2015;60(2):328–37. https://doi.org/10.1016/j.molcel.2015.09.001.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Wang X, Kaczor-Urbanowicz KE, Wong DT. Salivary biomarkers in cancer detection. Med Oncol. 2017;34(1):7. https://doi.org/10.1007/s12032-016-0863-4.

    Article  PubMed  CAS  Google Scholar 

  100. Yu FX, Zhang Y, Park HW, Jewell JL, Chen Q, Deng Y, Pan D, Taylor SS, Lai ZC, Guan KL. Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. Genes Dev. 2013;27(11):1223–32. https://doi.org/10.1101/gad.219402.113.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  101. Bao Y, Nakagawa K, Yang Z, Ikeda M, Withanage K, Ishigami-Yuasa M, Okuno Y, Hata S, Nishina H, Hata Y. A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription. J Biochem. 2011;150(2):199–208. https://doi.org/10.1093/jb/mvr063.

    Article  PubMed  CAS  Google Scholar 

  102. Seo J, Kim J. Regulation of Hippo signaling by actin remodeling. BMB Rep. 2018;51(3):151–6. https://doi.org/10.5483/bmbrep.2018.51.3.012.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  103. Guo L, Teng L. YAP/TAZ for cancer therapy: opportunities and challenges (review). Int J Oncol. 2015;46(4):1444–52. https://doi.org/10.3892/ijo.2015.2877.

    Article  PubMed  CAS  Google Scholar 

  104. Marsola APZC, Simões BP, Palma LC, Berzoti-Coelho MG, Burin SM, de Castro FA. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia. Med Oncol. 2018;35(3):26. https://doi.org/10.1007/s12032-018-1079-6.

    Article  PubMed  CAS  Google Scholar 

  105. Safari S, Movafagh A, Zare-Adollahi D, Ghadiani M, Riazi-Isfahani S, Safavi-Naini N, Omrani MD. MST1/2 and YAP1 gene expression in acute myeloid leukemia. Leuk Lymphoma. 2014;55(9):2189–91. https://doi.org/10.3109/10428194.2013.867493.

    Article  PubMed  Google Scholar 

  106. Kim TS, Lee DH, Kim SK, Shin SY, Seo EJ, Lim DS. Mammalian sterile 20-like kinase 1 suppresses lymphoma development by promoting faithful chromosome segregation. Cancer Res. 2012;72(20):5386–95. https://doi.org/10.1158/0008-5472.CAN-11-3956.

    Article  PubMed  CAS  Google Scholar 

  107. Hartmann EM, Campo E, Wright G, Lenz G, Salaverria I, Jares P, Xiao W, Braziel RM, Rimsza LM, Chan WC, Weisenburger DD, Delabie J, Jaffe ES, Gascoyne RD, Dave SS, Mueller-Hermelink HK, Staudt LM, Ott G, Beà S, Rosenwald A. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood. 2010;116(6):953–61. https://doi.org/10.1182/blood-2010-01-263806.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  108. Wang G, Yu X, Xia J, Sun J, Huang H, Liu Y. MicroRNA-9 restrains the sharp increase and boost apoptosis of human acute myeloid leukemia cells by adjusting the Hippo/YAP signaling pathway. Bioengineered. 2021;12(1):2906–14. https://doi.org/10.1080/21655979.2021.1915727.

    Article  PubMed  CAS  Google Scholar 

  109. Chorzalska A, Kim JF, Roder K, Tepper A, Ahsan N, Rao RSP, Olszewski AJ, Yu X, Terentyev D, Morgan J, Treaba DO, Zhao TC, Liang O, Gruppuso PA, Dubielecka PM. Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous Leukemia. Stem Cells Dev. 2017;26(9):656–77. https://doi.org/10.1089/scd.2016.0262.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  110. Yoshida M, Horiguchi H, Kikuchi S, Iyama S, Ikeda H, Goto A, Kawano Y, Murase K, Takada K, Miyanishi K, Kato J, Kobune M. miR-7977 inhibits the Hippo-YAP signaling pathway in bone marrow mesenchymal stromal cells. PLoS One. 2019;14(3):e0213220. https://doi.org/10.1371/journal.pone.0213220.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

No funding.

Author information

Authors and Affiliations

Authors

Contributions

NN and MK contributed to the conception, design. NN, BH, and MJ contributed to data collection and manuscript drafting. MK and MG illustrated the figure, and MK oversaw the study. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Maria Kavianpour.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Noorbakhsh, N., Hayatmoghadam, B., Jamali, M. et al. The Hippo signaling pathway in leukemia: function, interaction, and carcinogenesis. Cancer Cell Int 21, 705 (2021). https://doi.org/10.1186/s12935-021-02408-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12935-021-02408-7

Keywords

  • Hippo signaling pathway
  • Signaling
  • Leukemia
  • Hematologic neoplasms
  • Cancer